市場調査レポート
商品コード
1117106
質量分析計の世界市場予測(~2028年):製品別、プラットフォーム別、地域別の分析Mass Spectrometer Market Forecasts to 2028-Global Analysis By Product (Gas Chromatography Mass Spectrometer (GC-MS), Inductively Coupled Plasma Mass Spectrometer (ICP-MS)), Platform (Hybrid Mass Spectrometry, Single Mass Spectrometry) & By Geography |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
質量分析計の世界市場予測(~2028年):製品別、プラットフォーム別、地域別の分析 |
出版日: 2022年08月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2~3営業日
|
世界の質量分析計の市場規模は、2022年に48億2,000万米ドルとなり、予測期間中に8.5%のCAGRで拡大し、2028年までに78億7,000万米ドルに達すると予測されています。
当レポートでは世界の質量分析計市場を調査し、市場の促進要因・抑制要因、市場機会、COVID-19の影響、セグメント別の市場分析、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。
Note: North America, Europe, Asia Pacific, South America and Middle East & Africa are represented in above manner.
According to Stratistics MRC, the Global Mass Spectrometer Market is accounted for $4.82 billion in 2022 and is expected to reach $7.87 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Mass spectrometry is a technique which is used in the recognition of various types of chemical present in the sample. It is also used in the quantification of quantity of specific chemical in the sample. It identifies and quantities crucial proteins involved in disease and transformed phenotypes and standard diagnostic biomarkers for treatment. It is very common technique in systematic laboratories which helps in the study of biological and chemical properties of compounds. In life science area, mass spectrometry is primarily involved in the description and sequencing of proteins.
Market Dynamics:
Driver:
Growing investments and government initiatives in the industry
The increased investment in the pharmaceutical and biotechnology industries is one of the factors driving the market growth. The pharmaceutical and biotechnology industries will be driven by investments in critical areas such as the pharmaceutical and personalized medicine markets. Mass spectrometry is vital in the pharmaceutical industry, from drug discovery to late-stage development and clinical trials. As a result, the market is predictable to profit from increased funding from the pharmaceutical and biotechnology industries.
Restraint:
High cost
Due to innovative features and functionalities spectrometry instruments are equipped with priced at a premium. Apart from the system's cost, the cost of compliance of the system to industry standards is also very high. Owing to technological advancements and increased operational efficiencies, the demand for mass spectrometers has grown over the years. However, technological developments have increased system prices. The price of a spectrometer influences the purchase decision of end users. Pharmaceutical companies require many such systems, and hence, the capital cost increases significantly. Furthermore, academic research laboratories find it difficult to afford such systems, as they have controlled budgets. These are the major factors limiting the adoption of mass spectrometry systems among end users.
Opportunity:
Possibilities for development in developing markets
Because of the Greenfield enterprises being installed in several end-user industries in those international locations, China and India knowingly demand single mass spectrometers and hybrid spectrometry devices. These international sites' biopharmaceutical companies are powerful, and they must be contributing significantly to the growth of the markets.
Threat:
Expensive product affordability
Machine prices have increased owing to technological advancements. The rate of a spectrometer influences the acquisition selection of quit users. Pharmaceutical companies will require numerous of these structures, raising the capital cost significantly. Moreover, educational research laboratories find it difficult to raise funds for such structures owing to tight budgets. These are the major factors limiting the growth of the market.
The Pharmaceutical segment is expected to be the largest during the forecast period
The Pharmaceutical segment is expected to be the largest during the forecast period, owing to rising investments in improving the sensitivity and resolution of these instruments is a key factor driving revenue growth of this segment. Mass spectrometry is a powerful analytical tool that serves several applications in pharmaceutical and biomedical fields. Besides, it has opened new dimensions in the analysis of pharmaceuticals and complex metabolites of biological systems. When compared to other conventional analysis techniques, mass spectrometry is the only one for molecular weight determination, through which users can predict the molecular formula.
The Hybrid Mass Spectrometry segment is expected to have the highest CAGR during the forecast period
The Hybrid Mass Spectrometry segment is expected to have the highest CAGR during the forecast period owing to the extensive applications coupled with the technological advancements which are driving the growth of this segment. Moreover, their application and level of performance compared to other types of spectrometers. Hybrid mass spectrometry combines numerous mass-analyser components to achieve extreme performance in a single test. Increased performance of mass spectrometer can be measured in terms of higher sensitivity and resolving power, rapid data production & abundance of data-sets are additional set of benefits obtainable by hybrid mass spectrometers.
Region with highest share:
North America is projected to hold the largest market share during the forecast period owing to the presence of favourable government funding programs such as for research studies National Institutes of Health, funded a grant for biomedical research to the University of Georgia are the factors attributing for its largest share.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period due to the increase in acceptance of these technological platforms across various fields. Moreover, increasing technological adoption and government initiatives. Growing investments and funding in drug discovery development are also boosting the market. Technology plays a vital role in product development or improvement. Innovations in icon chromatography-mass spectrometry systems provide significant opportunities for the market in emerging countries to implement various applications such as environmental analysis, chemical analysis, and others. Growing demand for tandem and hyphenated techniques and the adoption of advanced mass spectrometry technologies such as increased speed, improved resolution, and high accuracy propel market growth.
Key players in the market
Some of the key players profiled in the Mass Spectrometer Market include Agilent Technologies, Analytik Jena, Bruker, Dani Instruments, Hiden Analytical, Jeol, Kore Technologies Ltd, Leco, Perkinelmer, Rigaku, Sciex, Shimadzu Corporation, Thermo Fisher Scientific and Waters Corporation.
Key Developments:
In January 2021: Bruker Corporation announced the supply of NMR spectrometers for protein research to three world-leading institutions, which are accelerating their research into functional structural biology and human disease.
In September 2021: Thermo Fisher Company launched the world's first net-zero mass spectrometer. This product is the first spectrometer developed under the ground-breaking IsoFootprint initiative in order to tackle CO2 emissions for more sustainable science. In June 2021, the company announced the official launch of the next-generation MS-based solution called Orbitrap IQ-X Tribrid mass spectrometer.
Products Covered:
Platforms Covered:
Applications Covered:
End Users Covered:
Regions Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options: